| INTRODUCTION
People living with chronic hepatitis C virus (HCV) infection often report a broad array of physical and mental symptoms [1] [2] [3] [4] including but not limited to, fatigue, musculoskeletal pain, poor appetite, nausea, abdominal pain, cognitive impairment, depression, anxiety, irritability and sleep distubance. 1, 5 Numerous studies have investigated health related quality of life (HRQOL) in patients living with chronic HCV. 6, 7 However, a comprehensive quantitative analysis of patients'
experiences of specific symptoms that may be associated with HCV has not been conducted. 5 The new direct acting antiviral (DAA) therapies to treat HCV are very well tolerated compared to previous treatments; nonetheless, they can still cause side effects, such as fatigue, nausea, and headache. [8] [9] [10] [11] Thus far, our understanding of patients' experiences with DAA therapy has been limited to data derived from industry-sponsored DAA trials. 12, 13 Those studies provided very useful information regarding the effects of DAAs on patients' HRQOL, work productivity, and fatigue. 14 However, no other symptom experiences have been evaluated from the patients' perspective during DAA therapy.
The impact of disease, treatment and viral cure on peoples' lives is nearly impossible to understand without direct input from patients themselves. Patients' experiences are evaluated using patientreported outcome (PRO) measures, defined as "any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else." 15 PRO measures are the best way to capture patients' experiences about how a disease, its treatment, or cure affects their lives in a meaningful way.
A recent literature review identified 22 key PRO concepts that were found to be important to people living with HCV in qualitative studies. 5 The majority of these concepts are specific symptoms such as depression, fatigue, anxiety, cognitive dysfunction, musculoskeletal pain, irritability, sleep problems, lack of appetite, and gastrointestinal symptoms. Many of these specific symptoms that concern patients have received inadequate attention in HCV clinical studies. Of the 18 PRO measures utilized in HCV clinical studies, only four have actually been developed or validated in the HCV population, three of which are broad HRQOL measures which are not designed to thoroughly measure specific symptoms or side effects. 6, 16, 17 In response to increasing recognition of the importance of evaluating patients' experiences of illness and treatment, the National
Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) initiative has developed a comprehensive well-evaluated set of self-report tools, some of which measure specific symptoms. 18, 19 PROMIS measures have been used in a few hepatology studies, 20, 21 one of which validated several instruments delivered via a computerized adaptive testing system in patients with cirrhosis. 20 PROMIS measures have several advantages over other PRO measures: items were developed using qualitative and quantitative methods; surveys are designed to measure a single symptom and not overlap with others; surveys are brief (4-8 items); and scores can be compared across other health conditions and populations.
In the current study, we evaluated the reliability and validity of several PROMIS short form measures and the Headache Impact Test (HIT-6), a symptom not assessed by PROMIS. 22 The specific aims of the study were to evaluate the following psychometric properties:
(1) internal reliability; (2) floor and ceiling effects; and (3) construct validity (structural validity, convergent validity, and known-groups validity).
| MATERIALS AND METHODS

| Parent study
The psychometric properties of PROMIS measures were evaluated using baseline data from the Patient-Reported Outcomes Project of HCV-TARGET ("PROP UP") (Clinical trial.gov: NCT02601820 
| Study design
Data from baseline assessments were used to conduct a cross-sectional study of the reliability and validity of the HIT-6 and 10 PRO-MIS measures. Patients who consented and completed baseline surveys were included in this analysis.
| Research participants
Inclusion/exclusion criteria have been previously reported. 23 Briefly, patients were invited to participate in PROP UP if they were diagnosed with chronic HCV infection of any genotype; English-speaking; age 21 years or older; and prescribed one of five DAA regimens.
For this analysis, we included data from a cohort of 961 patients who had completed baseline surveys at the time of data retrieval (11/28/2016).
| Measures
| PROMIS measures
The 10 PROMIS short forms included Fatigue-7a, Depression-8a, Anger-5a, Anxiety-4a, Pain Interference-8a, Sleep Disturbance-8a, Applied Cognition-General Concerns-8a, Belly Pain-6, Diarrhea-6, and Nausea/Vomiting-4 (available via www.HealthMeasures.net).
The short forms were used to measure symptoms most common or salient to HCV or DAA therapy. Each PROMIS short form includes a subset of items from a larger item bank that were the best performing items in terms of content validity and reliability. 18 Headaches have been reported as an adverse event during industrysponsored DAA trials, [8] [9] [10] [11] but no PROMIS instrument specifically measures this symptom. Therefore, we used the 6-item Headache Impact Test to measure headaches that could occur during treatment. 22 The six items are responded to on a 5-point Likert scale
ranging from "Never" to "Always." The final score is summed and can range from 36 to 78, with higher scores reflecting worse headaches.
| Memorial symptom assessment scale (MSAS)
The MSAS is a reliable and validated instrument used to evaluate 32 symptoms associated with common medical conditions treatment. 28 
| HCV-PRO
The HCV-PRO is a disease-specific survey that assesses well-being and HRQOL in people with chronic HCV. 30, 31 The measure was 
| Statistical analysis strategy
The internal consistency reliability of each measure was evaluated using point-and interval-estimates of Cronbach's alpha. We considered alpha > 0.70 to be an acceptable minimum criterion for establishing reliability in the cohort of patients studied. 35, 36 For generalization from our sample to a target population, we infer reliability in that population if the observed lower 95% confidence limit for alpha exceeds 0.70. 37 Due to the substantial number of participants who did not experience the symptom, the estimates of Cronbach's alpha for the PROMIS Belly Pain, Diarrhea, and Nausea/ Vomiting were computed using only the data from participants who reported the presence of that symptom because many patients did not experience this symptom at all. In sensitivity analyses used to evaluate the impact of this approach, the alpha estimates were also computed based on all participants.
Ceiling and floor effects were evaluated in terms of the proportion of participants who had the maximum score (or minimum
| 1003 score). 38 Skewness and other properties of the frequency distributions of the scores were examined via graphical descriptive methods.
Factor-analytic assessment of structural validity (ie, underlying unidimensionality) of each measure relied on unidimensional and multidimensional graded-response item-response-theory models. 39 Overall model fit was evaluated based on the root mean square error of approximation (RMSEA). 40 An RMSEA value less than or equal to 0.06 was considered to indicate good fit, a value within 0.06-0.08 is a fairly good fit, and a value above 0.10 is a poor fit. 41 The S chi-square test procedure was used to test the null hypothesis which states that the item-level fit is adequate. 42 Relative to longer questionnaires, shorter questionnaires provide less power and precision to detect and quantify item-level misfit. We assumed that item-level fit for the short-form measures is similar to the item-level fit for long-form measures. The standardized local dependence (LD) chi-square test procedure was used to detect items that are excessively related after controlling for the underlying domain: LD test statistic values larger than 10.0 identified items with substantial LD. 43 In sensitivity analyses, to evaluate the robustness of the main results to reasonable perturbation of the methods used, the LD tests were adjusted for multiple comparisons. Sensitivity analyses also included an additional check on the underlying dimensionality of the measure performed by fitting a bi-factor gradedresponse item-response-theory modelwith each identified LD pair or set of items as a second order factor. 44 Any LD violations were deemed negligible if they explained common variance (ECV) was at least 0.90. 45, 46 ECV represents the variance explained by the general factor in the bi-factor model.
To evaluate convergent validity, we used the absolute value of point-and interval-estimates of the Spearman correlations (q) between measures of theoretically-similar domains. For this purpose, for each of the PROMIS and HIT-6 measures, we identified item pairs which, logically, should be positively correlated. We anticipated that there should exist substantial positive correlations between those item pairs. We used Dancey and Reidy's classification which specifies that 0.40-0.70 is the range of a "moderate" correlation. 47 Known-groups validity helps to support construct validity if it can be demonstrated that an instrument discriminates between groups that are known to differ on a given construct. The extant literature in HCV is extremely limited on definitive groups that would differ according to precise symptoms. However, a few studies, though not all suggest that HRQOL and one symptom, fatigue, may differ among patients with and without cirrhosis. 16, [48] [49] [50] Based on this literature, the a priori analysis plan was to compare patients categorized as cirrhotic or noncirrhotic based on medical chart review (as described above). Secondarily, we used a three-category approach to better observe PRO scores in patients with and without cirrhosis, should experience greater symptoms. 51 Unless otherwise specified, all statistical computations were performed using SAS System software version 9.4 (SAS Institute, Cary, NC). Analysis of the graded-response item-response-theory models were performed using the SAS IRT procedure and using IRT-PRO software, version 4.1 (Scientific Software International, Lincolnwood, IL). PROMIS T-scores were computed using RSTUDIO software, version 1.0.136 (RStudio Inc.).
3 | RESULTS
| Patient characteristics
The characteristics of the 961 study participants at baseline are presented in Table 1 . Mean age was 57 (SD = 10.7) years old. In addition to having chronic HCV and liver disease, participants reported an average of 4 other health comorbidities (range 0-15).
| Missing values
The frequency of missing data among the HIT-6 and PROMIS short form scores were less than 2.2%. The frequency of missing data for the HCV-PRO score was 7.7%. We judged the reasons for the incomplete data to satisfy the "missing completely at random" crite- 
| Floor and ceiling effects
Ceiling effects were consistently low among all PRO measures ( < 4% of participants had scores at the upper limit), suggesting that all measures performed well in capturing severe symptoms at the upper limits of the scales (Table 2 ). In contrast, many patients did not report symptoms and therefore notable floor effects (range 30% to 59%) were observed for the HIT-6 and a majority of the PROMIS measures. Floor effects were small for PROMIS Fatigue (1.6%) and Sleep Disturbance (6.8%) indicating that most patients reported at least some mild fatigue and sleep disturbance problems. The HCV-PRO had a negligible floor (0.10%) effect and a small ceiling effect (5.9%).
| Structural validity
Findings supported the unidimensionality of the HIT-6, PROMIS measures, and HCV-PRO (Table 3) 
| Convergent validity
As shown in Table 4 , both the HIT-6 score and the PROMIS Belly 
| Known-groups validity
Differences in PRO scores between patients defined as noncirrhotic and cirrhotic via medical chart review were negligible (data not shown). In a subsequent analysis (Tables 5 and 6 ) of three liver disease categories (ie, noncirrhotic, MELD 6-12, MELD > 12), a severity-response trend was observed such that worse symptoms were associated with advancing liver disease. In particular, patients with MELD > 12 had higher (worse) scores on all symptoms compared to the other two groups, with mean differences ranging from 1.9 to 4.1. While the sample size of those with MELD > 12 was small (n = 37) and provided limited precision, the mean differences were comparable to established PROMIS minimally important differences reported in other medical populations. [24] [25] [26] [27] In the final knowngroups validity analysis, we found positive correlations between a greater number of comorbid health conditions and worse symptom scores, consistent with prior studies. 51 
| DISCUSSION
The objectives of the current study were to establish the reliability and validity of several PRO measures, specifically 10 PROMIS measures and the HIT-6, to evaluate specific symptoms in patients with chronic HCV. Given the large national sample of patients recruited for the PROP UP study, it represented a reasonable platform in which to evaluate the psychometric properties of several new PRO measures that could be useful in future patient-centered outcomes research in the field of chronic HCV. The overall findings from this study suggest that the psychometric properties of these PROs are sufficiently satisfactory to be used in future HCV studies, with specific caveats noted below.
The internal consistency of the symptom scales was well above the acceptable limit of 0.70 (range: 0.87-0.98) indicating very good to excellent reliability. Only one exception was noted for the PRO-MIS Nausea/Vomiting measure which appears to be multidimensional. This measure had a lower reliability because its four items tap three constructs (nausea, poor appetite, vomiting), which while associated, are not highly correlated.
None of the PROs had notable ceiling effects, which is critically important to investigations that need to capture very severe symptoms, as might be the case with patients listed for liver transplantation. Thus, these PROs are suitable to evaluate patients' experiences of severe and debilitating symptoms.
In contrast, floor effects were notable for most of the PROs, Unidimensionality was assessed using a one-factor confirmatory factor analysis. f Factor loading of the item: "In the past 7 days, how often did you have enough energy to exercise strenuously?". were observed for the HIT-6 and PROMIS Belly Pain, which may be because the general "pain" item we used to evaluate headache and abdominal pain was too nonspecific. The absence of other legacy measures or items impeded our ability to adequately examine convergent validity for a couple of scales, representing one limitation of this study.
Finally, we explored known-groups validity in patients with and without cirrhosis, with varying levels of liver disease, and with a range of comorbid medical conditions. Differences in PRO scores
were negligible between patients with no cirrhosis and mild cirrhosis, however, patients with advanced cirrhosis (MELD > 12) had worse symptom scores than patients with no or minimal cirrhosis, by 1.9 to 4.1 point differences. In particular, it is reasonable to expect that gastrointestinal symptoms (nausea, abdominal pain, and diarrhea) and pain would be worse in patients with advanced cirrhosis due to decompensation compared to those with minimal or no cirrhosis (point differences ≥ 3). This finding is consistent with Bajaj et al who found differences between patients with compensated and decompensated cirrhosis on several of the same PROMIS measures. 20 The lack of differentiation in this study between patients with no cirrhosis and those with mild cirrhosis may be because the former group had stage 2-3 fibrosis, while the latter group had early stage 4 fibrosis; the small difference in liver disease stage may explain the similarity in symptoms in these two groups. Unfortunately, liver disease staging data are unavailable to substantiate this hypothesis, although
we know that at the time of enrollment into this study, many payers only covered DAA therapy in patients with advanced fibrosis or cirrhosis. Future studies with the PROMIS measures could determine if other items from the larger item banks could provide better differentiation between these fibrosis levels. In a second analysis of knowgroups validity, we found evidence of an association between the 
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To conclude, the current study found the psychometric proper- The statements presented in this article are solely the responsibility of the authors and do not necessarily represent the
